With recent approval of the first two gene therapies for haemophilia A and B,...
Hemophilia B (HB) is a rare, hereditary disease caused by a defect in the...
The advent of new treatment options over the last decades has markedly improved the...
Thromboembolic events are increasingly reported in the aging haemophilia population. The purpose of this...
Haemophilia treatment centres (HTCs) and healthcare providers (HCPs) will need to adapt to a...
Recent recommendations of core outcome sets for haemophilia highlight the need for including measures...
After decades of investigation, gene therapy has received regulatory approval to treat hemophilia. However,...
Primary prophylaxis has significantly reduced the number of orthopedic surgical procedures performed on patients...
The standard of care in severe haemophilia A is prophylaxis, which has historically aimed...
Data from 21 years (2000–2020) of haemovigilance were used to assess human immunodeficiency virus (HIV),...